The DRG collaborates with AstraZeneca and the Moss Labs for Translational Science to describe small molecule activators of KCC2, which restore the activity of benzodiazepines in status epilepticus
Goldman DRG engineers new drugs that improve activity of adoptive NK cells for GBM
Partnership with Cannex Scientific to study novel drugs for neuro-psychiatry and tissue injury
Published in a 2020 issue of iScience, the DRG uncover mechanisms that drive response or resistance to cancer immunotherapy
The DRG publishes an article in Cancer Research describing a novel nanotherapeutic that can re-active natural killer cells and improve killing of adoptive cell therapies
An interdisciplinary team led by Aaron and Dr. Ilana Braun deployed the tools for cancer biology to study anxiety in mice. New discoveries leading to novel biomarkers of anxiolysis in humans.
Drug Resistance Group identifies a novel 3-drug combination by targeting the glucose-6-phosphate dehydrogenase during metabolic remodeling. Visit the article
In collaboration with Dr. Martin Nowak, we describe a novel mechanism of drug-induced resistance, which emerges through clonal cooperation dynamics in heterogeneous cancers. Read the article!